Abstract
Background Non-invasive finger-cuff monitors measuring cardiac index and vascular tone (SVRI) classify emergency department (ED) patients with acute heart failure (AHF) into three otherwise-indistinguishable subgroups. Our goals were to validate these “hemodynamic profiles” in an external cohort and assess their association with clinical outcomes.
Methods AHF patients (n=257) from five EDs were prospectively enrolled in the validation cohort (VC). Cardiac index and SVRI were measured with a ClearSight finger-cuff monitor (formerly NexFin, Edwards Lifesciences) as in a previous study (derivation cohort, DC, n=127). A control cohort (CC, n=127) of ED patients with sepsis was drawn from the same study as the DC. K-means cluster analysis previously derived two-dimensional (cardiac index and SVRI) hemodynamic profiles in the DC and CC (k=3 profiles each). The VC was subgrouped de novo into three analogous profiles by unsupervised K-means consensus clustering. PERMANOVA tested whether VC profiles 1-3 differed from profiles 1-3 in the DC and CC, by multivariate group composition of cardiac index and vascular tone.
Profiles in the VC were compared by a primary outcome of 90-day mortality and a 30-day ranked composite secondary outcome (death, mechanical cardiac support, intubation, new/emergent dialysis, coronary intervention/surgery) as time-to-event (survival analysis) and binary events (odds ratio, OR). Descriptive statistics were used to compare profiles by two validated risk scores for the primary outcome, and one validated score for the secondary outcome.
Results The VC had median age 60 years (interquartile range {49-67}), and was 45% (n=116) female. Multivariate profile composition by cardiac index and vascular tone differed significantly between VC profiles 1-3 and CC profiles 1-3 (p=0.001, R2=0.159). A difference was not detected between profiles in the VC vs. the DC (p=0.59, R2=0.016).
VC profile 3 had worse 90-day survival than profiles 1 or 2 (HR = 4.8, 95%CI 1.4-17.1). The ranked secondary outcome was more likely in profile 1 (OR = 10.0, 1.2-81.2) and profile 3 (12.8, 1.7-97.9) compared to profile 2. Diabetes prevalence and blood urea nitrogen were lower in the high-risk profile 3 (p<0.05). No significant differences between profiles were observed for other clinical variables or the 3 clinical risk scores.
Conclusions Hemodynamic profiles in ED patients with AHF, by non-invasive finger-cuff monitoring of cardiac index and vascular tone, were replicated de novo in an external cohort. Profiles showed significantly different risks of clinically-important adverse patient outcomes.
Competing Interest Statement
Author Disclosures of Potential Conflicts of Interest: PL Consultant: Apex Innovations AstraZeneca BMS Mespere Novartis Cardionomics Baim Institute Ortho Clinical Diagnostics Roche Diagnostics Siemens Hospital Quality Foundation. Research Support: American Heart Association Beckman Coulter Agency for Healthcare Research and Quality (AHRQ) Blue Cross Blue Shield of Michigan Foundation (BCBSMF) Emergency Medicine Foundation Edwards Lifesciences CardioSounds Michigan Department of Health and Human Services Michigan Health Endowment Fund Patient Centered Outcome Research Institute National Institutes of Health (NIH)/National Institute on Minority Health and Health Disparities NIH/National Heart Lung Blood Institute (NHLBI) Other: Past Chair of the Accreditation Oversight Committee for the American College of Cardiology (ACC) and a member of the ACC National Cardiovascular Data Registry Oversight Committee. PP has received Research Support in the last one year: Roche Beckman-Coulter Siemens Ortho-Diagnostics Abbott AHRQ NEH has received Research Support from: BCBSMF Indiana Clinical Translational Science Institute (CTSI) Indiana University SM, PM, SH, SG, MBW, XL, DX report no conflicts of interest.
Funding Statement
Funding Sources/Disclosures: Edwards Lifesciences Investigator-Initiated Grant The sponsor had no role in the study conception, design, data analysis, or primary drafting of the manuscript. The sponsor provided the ClearSight monitoring platforms to Wayne State (WSU) and Indiana University (IUSM). The sponsor was blinded to outcomes and the analysis plan. The sponsor provided funding for WSU and IUSM research support staff to facilitate enrollment and data management, as well as investigator time for authors PL and PP. The primary/corresponding author NEH received no direct or indirect support from Edwards Lifesciences.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional review boards of Wayne State University and Indiana University gave ethical approval of this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Prior Presentations: None
Funding Sources/Disclosures: Edwards Lifesciences Investigator-Initiated Grant
The sponsor had no role in the study conception, design, data analysis, or primary drafting of the manuscript. The sponsor provided the ClearSight monitoring platforms to Wayne State (WSU) and Indiana University (IUSM). The sponsor was blinded to outcomes and the analysis plan. The sponsor provided funding for WSU and IUSM research support staff to facilitate enrollment and data management, as well as investigator time for authors PL and PP. The primary/corresponding author NEH received no direct or indirect support from Edwards Lifesciences.
Author Disclosures of Potential Conflicts of Interest: PL - Consultant: Apex Innovations, AstraZeneca, BMS, Mespere, Novartis, Cardionomics, Baim Institute, Ortho Clinical Diagnostics, Roche Diagnostics, Siemens, Hospital Quality Foundation.
Research Support: American Heart Association, Beckman Coulter, Agency for Healthcare Research and Quality (AHRQ), Blue Cross Blue Shield of Michigan Foundation (BCBSMF), Emergency Medicine Foundation, Edwards Lifesciences, CardioSounds, Michigan Department of Health and Human Services, Michigan Health Endowment Fund, Patient Centered Outcome Research Institute, National Institutes of Health (NIH)/National Institute on Minority Health and Health Disparities, NIH/National Heart Lung Blood Institute (NHLBI). Other: Past Chair of the Accreditation Oversight Committee for the American College of Cardiology (ACC) and a member of the ACC’s National Cardiovascular Data Registry Oversight Committee.
PP – In the last one year, PP has received Research Support: Roche, Beckman-Coulter, Siemens, Ortho-Diagnostics, Abbott, and AHRQ
NEH – Research Support: BCBSMF, Indiana Clinical Translational Science Institute (CTSI)
SM, PM, SH, SG, MBW, XL, DX report no conflicts of interest.
Data Availability
Data produced in the present work, and code for reproduction of the results in R, are contained in peer review submission. These will be made available upon publication, or reasonable request.
